Baird Medical Investment Holdings Limited, along with its subsidiaries manufactures microwave ablation and other medical devices for minimally invasive tumor treatment. The company is headquartered in Guangzhou, China.
| Revenue (TTM) | $22.54M |
| Gross Profit (TTM) | $18.88M |
| EBITDA | $-24.53M |
| Operating Margin | -104.10% |
| Return on Equity | -77.60% |
| Return on Assets | -21.70% |
| Revenue/Share (TTM) | $0.81 |
| Book Value | $1.52 |
| Price-to-Book | 1.10 |
| Price-to-Sales (TTM) | 1.55 |
| EV/Revenue | 2.136 |
| EV/EBITDA | 133.58 |
| Quarterly Earnings Growth (YoY) | -0.30% |
| Quarterly Revenue Growth (YoY) | -39.00% |
| Shares Outstanding | $31.98M |
| Float | $12.11M |
| % Insiders | 64.85% |
| % Institutions | 0.75% |
Volatility is currently expanding
Revenue increase driven by significant growth in the United States and other strategic markets Revenue increase driven by significant growth in the United States and other strategic markets
NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan (“DRAP”), further supporting the Company's commercial activities in the country.
NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”) and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand (“Alpmed”), a China-based innovator in irreversible electroporation (“IRE”) technology, announced the signing of a strategic cooperation agreement to establish a long-term partnership focused on global development and commercialization of next-generation IRE technologies.
First procedures in two new markets highlight growing global adoption of Baird Medical's minimally invasive microwave ablation technology NEW YORK, June 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of the first procedures using its MWA technology in Vietnam and Argentina.
Enhanced U.S. Presence Centralizes Operations as Company Executes Global Growth Strategy NEW YORK, June 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA ) technology, today announced the relocation of its global headquarters to the U.S., with the establishment of a new corporate office in New York, NY.
Full year 2025 revenue of $22.5 million, impacted by policy-driven slowdown in Mainland China Advancing global expansion with appointment of seasoned commercial leader, Mark Saxton, as CEO of Baird Medical U.S. to lead commercial ramp in the United States NEW YORK, April 29, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its financial results for the full year ended December 31, 2025 and provided an update on key strategic and operational initiatives.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDMD and any ticker you trade — then tracks every position and per-strategy win rate.
